Q-omics provides the consensus-scored MYH7 profile across patient tissues and cancer cell-line models. MYH7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MYH7 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MYH7 RNA expression shows 14,544 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRC, and PDAC as cancer lineages where MYH7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYH7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYH7 survival associations across molecular data types. MYH7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYH7 RNA expression–survival associations across cancer types. High MYH7 expression shows unfavorable associations in UCEC and HNSC, but favorable associations in UVM, CESC, LGG and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MYH7 RNA expression.
This table summarizes MYH7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MYH7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYH7 shows lower tumor expression in KIRC, HNSC, KICH, KIRP and PRAD and higher tumor expression in LUAD. The KIRC box plot shows higher MYH7 RNA expression in normal versus tumor tissue (log2 FC = −0.290, t-test p < 0.001).
This table shows molecular features associated with MYH7 in patient tissues and cancer cell lines. In patient samples, MYH7 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYH7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
